Logo
Contact Us

Transforming Cancer Care Through Data

COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.

Banner-bg-1
Learn More
home-banner
Banner-bg-2

Powering the Next Generation of Cancer Research

Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.

home-icon-1

For Research and Development Teams

COTA'S curated database of oncology patient data allows drug development teams to expedite timelines by giving them the tools to generate and test hypotheses and identify subpopulations of interest, identify predictors of treatment response and inform go/no-go research decisions.
Learn More
home-icon-2

For Regulatory Teams

Use COTA data to support regulatory submissions and augment clinical trials with cohorts of patients from real-world settings, supplement clinical trial data with real-world benchmarks, and provide external validity of data collected in single-arm studies.
Learn More
home-icon-3

For Commercial Teams

Post approval, COTA data can help validate commercial strategy hypotheses, support label expansion studies/life cycle management/patent considerations, and conduct Phase IV studies.
Learn More
home-icon-5

For HEOR Teams

Utilize COTA data to carry out essential post-marketing studies that validate safety and patient outcomes, respond to inquiries from health authorities and payers, and support new dosing schedules, routes of administration, among other requirements.
Learn More
home-icon-4

For Providers

COTA’s data curation service and oncology analytics solution help oncology practices and cancer centers make sense of fragmented and often incomplete EHR data.
Learn More
home-icon-1

For Research and Development Teams

COTA's curated database of oncology patient data allows drug development teams to expedite timelines by giving them the tools to generate and test hypotheses and identify subpopulations of interest, identify predictors of treatment response and inform go/no-go research decisions.
Learn More
home-icon-2

For Regulatory Teams

Use COTA data to support regulatory submissions and augment clinical trials with cohorts of patients from real-world settings, supplement clinical trial data with real-world benchmarks, and provide external validity of data collected in single-arm studies.
Learn More
home-icon-3

For Commercial Teams

Post approval, COTA data can help validate commercial strategy hypotheses, support label expansion studies/life cycle management/patent considerations, and conduct Phase IV studies.
Learn More
home-icon-5

For HEOR Teams

Utilize COTA data to carry out essential post-marketing studies that validate safety and patient outcomes, respond to inquiries from health authorities and payers, and support new dosing schedules, routes of administration, among other requirements.
Learn More
home-icon-4

For Cancer Centers and Oncologists

COTA’s data curation service and oncology analytics solution help oncology practices and cancer centers make sense of fragmented and often incomplete EHR data.
Learn More
home-icon-1

For Research and Development Teams

COTA's curated database of oncology patient data allows drug development teams to expedite timelines by giving them the tools to generate and test hypotheses and identify subpopulations of interest, identify predictors of treatment response and inform go/no-go research decisions.
Learn More
home-icon-2

For Regulatory Teams

Use COTA data to support regulatory submissions and augment clinical trials with cohorts of patients from real-world settings, supplement clinical trial data with real-world benchmarks, and provide external validity of data collected in single-arm studies.
Learn More
home-icon-3

For Commercial Teams

Post approval, COTA data can help validate commercial strategy hypotheses, support label expansion studies/life cycle management/patent considerations, and conduct Phase IV studies.
Learn More
home-icon-5

For HEOR Teams

Utilize COTA data to carry out essential post-marketing studies that validate safety and patient outcomes, respond to inquiries from health authorities and payers, and support new dosing schedules, routes of administration, among other requirements.
Learn More
home-icon-4

For Cancer Centers and Oncologists

COTA’s data curation service and oncology analytics solution help oncology practices and cancer centers make sense of fragmented and often incomplete EHR data.
Learn More

Trusted by top biopharma and providers:

The Highest-Quality Cancer RWD and Insights at Your Fingertips

COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.

  • Oncology-focused dataset in hematologic and solid tumor cancers including: Multiple Myeloma, Acute Myeloid Leukemia, diffuse Large B Cell Lymphoma, NSCLC, and more.
  • 2M+ cancer patient lives
  • 50/50 academic vs. community treatment settings
Learn More
home-image-1
home-partner-1

How COTA Partners with Life Sciences Teams

Curated Real-World Datasets

Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.

Real-World Insights and Support

Get expert clinical insights, study design support, and statistical analysis.

Learn More

What Our Clients are Saying

We are using more data from COTA in our control arm than any other RWD provider
Senior Executive
Top 5 Pharma Company
We utilized COTA's RWD platform to uncover insights about real-world treatment patterns and outcomes across their multiple myeloma patient population
Dr. Harsh Parmar
Oncologist at Hackensack Meridian Health

We are using more data from COTA in our control arm than any other RWD provider

Senior Executive

Top 5 Pharma Company

Resources

Powering the Next Generation of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical…

Read More

Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence

Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an…

Read More

COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients

For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And…

Read More
View All Resources
home-blog-2
home-blog-1

Bring Clarity to Your Cancer Research

Partner with COTA for the highest-quality curated cancer patient datasets.

home-cta-1
Learn More
Logo
footer-background
Solutions
Products & Services
About Us
Follow Us
© 2025 COTA. All rights reserved.